162 related articles for article (PubMed ID: 20492890)
1. [Psoriasiform skin reactions during treatment with etanercept].
Santos-Juanes J; Galache C
Actas Dermosifiliogr; 2010 May; 101 Suppl 1():106-10. PubMed ID: 20492890
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
3. Psoriasiform reactions to anti-tumor necrosis factor α therapy.
Nguyen K; Vleugels RA; Velez NF; Merola JF; Qureshi AA
J Clin Rheumatol; 2013 Oct; 19(7):377-81. PubMed ID: 24048106
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
6. Recall injection-site reactions to etanercept in a patient with psoriasis.
Papadavid E; Makris M; Dalamaga M; Kalogeromitros D; Stavrianeas N
Clin Exp Dermatol; 2009 Apr; 34(3):414-5. PubMed ID: 19120391
[No Abstract] [Full Text] [Related]
7. Psoriasiform and pustular eruption induced by etanercept and infliximab.
Kuhara T; Watanabe D; Iwahori Y; Tamada Y; Yamamura M; Matsumoto Y
Eur J Dermatol; 2009; 19(4):388-9. PubMed ID: 19467963
[No Abstract] [Full Text] [Related]
8. [Etanercept and neoplasms].
García-Rabasco A; Sánchez-Carazo JL; Esteve A
Actas Dermosifiliogr; 2010 May; 101 Suppl 1():88-96. PubMed ID: 20492887
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
Joyau C; Veyrac G; Dixneuf V; Jolliet P
Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
[TBL] [Abstract][Full Text] [Related]
10. [Adverse events during biological therapy -- focusing on dermatological side-effects].
Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept.
Peek R; Scott-Jupp R; Strike H; Clinch J; Ramanan AV
Ann Rheum Dis; 2006 Sep; 65(9):1259. PubMed ID: 16905590
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.
Sfikakis PP; Iliopoulos A; Elezoglou A; Kittas C; Stratigos A
Arthritis Rheum; 2005 Aug; 52(8):2513-8. PubMed ID: 16052599
[TBL] [Abstract][Full Text] [Related]
14. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous lupus induced by etanercept in rheumatoid arthritis].
Abourazzak FE; Guggenbuhl P; Perdriger A; Meadeb J; Gando-Cocley N; Chevrant-Breton J; Hajjaj-Hassouni N; Chalès G
Rev Med Interne; 2008 Sep; 29(9):744-7. PubMed ID: 18676065
[TBL] [Abstract][Full Text] [Related]
16. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
17. Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.
Lamrock E; Brown P
Australas J Dermatol; 2012 Nov; 53(4):e87-90. PubMed ID: 23157794
[TBL] [Abstract][Full Text] [Related]
18. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis.
Soliotis F; Glover M; Jawad AS
Ann Rheum Dis; 2002 Sep; 61(9):850-1. PubMed ID: 12176818
[No Abstract] [Full Text] [Related]
19. Anti-tumor necrosis factor-alpha-induced psoriasis.
Sari I; Akar S; Birlik M; Sis B; Onen F; Akkoc N
J Rheumatol; 2006 Jul; 33(7):1411-4. PubMed ID: 16821276
[TBL] [Abstract][Full Text] [Related]
20. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
